Zobrazeno 1 - 3
of 3
pro vyhledávání: '"the EBL2002 Study group"'
Autor:
Houreratou Barry, Gaudensia Mutua, Hannah Kibuuka, Zacchaeus Anywaine, Sodiomon B. Sirima, Nicolas Meda, Omu Anzala, Serge Eholie, Christine Bétard, Laura Richert, Christine Lacabaratz, M. Juliana McElrath, Stephen De Rosa, Kristen W. Cohen, Georgi Shukarev, Cynthia Robinson, Auguste Gaddah, Dirk Heerwegh, Viki Bockstal, Kerstin Luhn, Maarten Leyssen, Macaya Douoguih, Rodolphe Thiébaut, the EBL2002 Study group
Publikováno v:
PLoS Medicine, Vol 18, Iss 10 (2021)
Background We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. Methods and findings In this randomised,
Externí odkaz:
https://doaj.org/article/7f50b4c25b664eea9599a273130f7e74
Autor:
Zacchaeus Anywaine, Houreratou Barry, Omu Anzala, Gaudensia Mutua, Sodiomon B. Sirima, Serge Eholie, Hannah Kibuuka, Christine Bétard, Laura Richert, Christine Lacabaratz, M. Juliana McElrath, Stephen C. De Rosa, Kristen W. Cohen, Georgi Shukarev, Michael Katwere, Cynthia Robinson, Auguste Gaddah, Dirk Heerwegh, Viki Bockstal, Kerstin Luhn, Maarten Leyssen, Rodolphe Thiébaut, Macaya Douoguih, on behalf of the EBL2002 Study group
Publikováno v:
PLoS Medicine
PLoS Medicine, Public Library of Science, 2022, 19 (1), pp.e1003865. ⟨10.1371/journal.pmed.1003865⟩
PLoS Medicine, Vol 19, Iss 1 (2022)
PLoS Medicine, 2022, 19 (1), pp.e1003865. ⟨10.1371/journal.pmed.1003865⟩
PLoS Medicine, Vol 19, Iss 1, p e1003865 (2022)
PLoS Medicine, Public Library of Science, 2022, 19 (1), pp.e1003865. ⟨10.1371/journal.pmed.1003865⟩
PLoS Medicine, Vol 19, Iss 1 (2022)
PLoS Medicine, 2022, 19 (1), pp.e1003865. ⟨10.1371/journal.pmed.1003865⟩
PLoS Medicine, Vol 19, Iss 1, p e1003865 (2022)
Background Reoccurring Ebola outbreaks in West and Central Africa have led to serious illness and death in thousands of adults and children. The objective of this study was to assess safety, tolerability, and immunogenicity of the heterologous 2-dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::595187d550e949bc1ea71e37fe71085e
http://europepmc.org/articles/PMC8752100
http://europepmc.org/articles/PMC8752100
Autor:
Barry, Houreratou, Mutua, Gaudensia, Kibuuka, Hannah, Anywaine, Zacchaeus, Sirima, Sodiomon B, Meda, Nicolas, Anzala, Omu, Eholie, Serge, Bétard, Christine, Richert, Laura, Lacabaratz, Christine, McElrath, M Juliana, De Rosa, Stephen, Cohen, Kristen W, Shukarev, Georgi, Robinson, Cynthia, Gaddah, Auguste, Heerwegh, Dirk, Bockstal, Viki, Luhn, Kerstin, Leyssen, Maarten, Douoguih, Macaya, Thiébaut, Rodolphe, EBL2002 Study group
BACKGROUND: We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. METHODS AND FINDINGS: In this randomised
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::d30c40084b1bb43ec7fa6a3a1ce5c8f7
